ReviewWorld journal of gastroenterology2015
Non-invasive diagnosis of liver fibrosis and cirrhosis.
Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 178 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
178 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Diagnosis of Liver Fibrosis Using Artificial Intelligence: A Systematic Review.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Association between serum ferritin level and the various stages of non-alcoholic fatty liver disease: A systematic review.Frontiers in medicine · 2022Pooled it
- Pooled it
- Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial.Scientific reports · 2025Trial
- Trial
- Trial
- Nutritional-inflammatory indices optimize the diagnostic performance of FIB-4 for advanced fibrosis/cirrhosis in patients with benign liver disease.Annals of medicine · 2026Article
- Serum Gremlin 1 Remains Elevated Following Successful Direct-Acting Antiviral Therapy for Chronic Hepatitis C.Viruses · 2026Article
- Differentiating advanced from non-advanced hepatic fibrosis: a hybrid deep learning-radiomics model leveraging synthetic contrast-enhanced CT from CycleGAN.Abdominal radiology (New York) · 2026Article
- Platelet and Doppler ultrasound signatures of histological fibrosis in chronic liver disease: a correlation study based on Ishak staging.Journal of ultrasound · 2026Article
- PERSoN4: A multiparametric ultrasound model to improve CEUS LI-RADS for HCC.JHEP reports : innovation in hepatology · 2026Article
- Preliminary insights into gut microbiome shifts as screening proxy for MASLD disease progression.Scientific reports · 2026Article
- Ligature-induced periodontitis exacerbates high-carbohydrate/high-fat diet-induced fatty liver in mice under non-diabetic conditions.BMC oral health · 2026Article
- Research Progress on the Application of Radiomics and Deep Learning in Liver Fibrosis.Journal of imaging · 2026Review
- Epidemiological characteristics, genotype patterns, and treatment outcomes in chronic hepatitis C patients receiving direct-acting antivirals: a cohort study from Istanbul, Türkiye.BMC infectious diseases · 2026Observational
- Does Gd-EOB-DTPA-enhanced T1 mapping have a role in the staging of fibrosis and inflammation in autoimmune hepatitis? A prospective study.Abdominal radiology (New York) · 2026Article
- Article
- Exploring potential associations between blood metabolites and cirrhosis risk: a Mendelian randomization and LC-MS/MS analysis.Frontiers in medicine · 2026Article
- Analysis of aspartate aminotransferase-to-platelet ratio index and liver fibrosis in biliary atresia.Journal of the colleges of medicine of South Africa · 2026Article
- Serum Bile Acid Profiling Across the Full Spectrum of HBV-Related Liver Diseases in Chinese Population: Implications for Diagnosis and Treatment Assessment.Biomedicines · 2025Article
118 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The evaluation and follow up of liver fibrosis and cirrhosis have been traditionally performed by liver biopsy. However, during the last 20 years, it has become evident that this "gold-standard" is imperfect; even according to its proponents, it is only "the best" among available methods. Attempts at uncovering non-invasive diagnostic tools have yielded multiple scores, formulae, and imaging modalities. All are better tolerated, safer, more acceptable to the patient, and can be repeated essentially as often as required. Most are much less expensive than liver biopsy. Consequently, their use is growing, and in some countries the number of biopsies performed, at least for routine evaluation of hepatitis B and C, has declined sharply. However, the accuracy and diagnostic value of most, if not all, of these methods remains controversial. In this review for the practicing physician, we analyze established and novel biomarkers and physical techniques. We may be witnessing in recent years the beginning of the end of the first phase for the development of non-invasive markers. Early evidence suggests that they might be at least as good as liver biopsy. Novel experimental markers and imaging techniques could produce a dramatic change in diagnosis in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.